These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8966654)

  • 1. [Intra-cavernous injections of vasoactive drugs. A 10-year experience at an andrologic center].
    Pozza D; Ossanna P; Cicchinelli C; Pozza M; Rizzo GL; Marchionni L
    Minerva Urol Nefrol; 1996 Sep; 48(3):163-7. PubMed ID: 8966654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavernosal administration of papaverine in a blind patient.
    Choi WH; Reynard JM; Dick JA
    Br J Urol; 1996 Jun; 77(6):922-3. PubMed ID: 8705238
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug treatment of sexual disorders in men].
    Slob AK; Gianotten WL
    Ned Tijdschr Geneeskd; 1996 Oct; 140(41):2029-32. PubMed ID: 8965939
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of one-side and bilateral intracavernosal papaverine injection on a Doppler study of the penis.
    Ghafoori M; Hoseini K; Shakiba M
    Int J Impot Res; 2009; 21(6):382-6. PubMed ID: 19847184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and treatment of impotence. Indications of intracavernous injections].
    Giuliano F; Blanchet P; Benoît G; Jardin A
    Presse Med; 1994 Sep; 23(27):1257-62. PubMed ID: 7971860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience.
    Copel L; Katz R; Blachar A; Sosna J; Sheiman RG
    Radiology; 2005 Dec; 237(3):986-91. PubMed ID: 16237136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The relationship of cavernous oxygen tension with erectile dysfunction of vascular origin].
    Romero-Tejada JC; Fernández Borrell A; Fernández Arjona M; Pereira Sanz I
    Arch Esp Urol; 1998 Nov; 51(9):919-22. PubMed ID: 9887565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
    Chen RN; Lakin MM; Montague DK; Ausmundson S
    J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acceptability of auto-injection of vasoactive drugs in the treatment of erectile dysfunction].
    Ribé Subirà N; Vives A; Jurado C; Rajmil O; Pomerol JM
    Arch Esp Urol; 1999 Nov; 52(9):973-7. PubMed ID: 10633965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous injections of vasoactive substances for the treatment of impotence.
    Zorgniotti AW
    Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1620. PubMed ID: 3835353
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device.
    Chun SS; Fenemore J; Heaton JP; Johnston B; Morales A
    Int J Impot Res; 1996 Dec; 8(4):221-5. PubMed ID: 8981171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction.
    Gheorghiu S; Godschalk M; Gentili A; Mulligan T
    J Urol; 1996 Jul; 156(1):80-1. PubMed ID: 8648844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
    Shamloul R; El-Dakhly M; Ghanem H; Gadallah A; Mokhtar H
    J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance to longterm vasoactive intracavernous therapy.
    Pagliarulo A; Ludovico GM; Cirillo-Marucco E; Corvasce A; Pagliarulo G
    Int J Impot Res; 1996 Jun; 8(2):63-4. PubMed ID: 8858392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complications of intracavernous pharmacologic infusion in impotence. Long-term results].
    Pastorini S; Marino G; Cocimano V; Griffa D; Pugno E
    Minerva Urol Nefrol; 1993 Sep; 45(3):109-12. PubMed ID: 8278876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.